Arrowhead Pharmaceuticals might notch more gains as the biotechnology company prepares to launch information connected to scientific trials for its treatment for an extremely typical medical condition, according to Morgan Stanley. The financial investment bank updated the pharma stock to obese from equivalent weight. It likewise treked its cost target on shares to $100 from $78, indicating 44.4% upside from Monday’s close. Arrowhead has actually currently been on fire of late. The stock is up more than 473% over the previous year. Nevertheless, expert Michael Ulz believes shares have much more space to run. ARWR 1Y mountain ARWR 1-yr chart “We anticipate momentum to continue ahead of [phase three clinical trial] information [for Plozasiran] in 3Q26, where we anticipate favorable information to open a multibillion-dollar chance that stays underappreciated,” expert Ulz stated in a note to customers. “This integrated with pipeline optionality adds to a beneficial outlook. Arrowhead Pharmaceuticals is anticipated to launch information from the 3rd stage of research studies on its investigational RNA disturbance restorative Plozasiran in the 3rd quarter of 2026– a relocation that might improve its stock, according to Morgan Stanley. The medication is created to deal with clients with extreme hypertriglyceridemia, a condition that impacts one-in-five grownups in the U.S., according to non-profit medical center Cleveland Center. “Information from research studies of plozasiran (Redemplo) in extreme hypertriglyceridemia are “anticipated to drive ongoing momentum,” Ulz composed. “Based upon previous information and a likewise created research study with a similar client population … we anticipate favorable outcomes.” “While interest around SHTG has actually currently driven noteworthy share gratitude, we see chance for additional advantage supported by our greater sales expectations,” Ulz composed. Morgan Stanley’s call falls in line with agreement on Wall Street. Of the 13 experts covering the stock, 10 have a buy or strong buy score on shares, LSEG information programs.
Related Articles
Add A Comment